If things go as planned, merger news could arrive as soon as next week:
Guardian Angel Group Inc. provides timeline regarding merger with Healthcare of Today, Inc.
Houston Texas, Feb 12, 2010 (M2 PRESSWIRE via COMTEX) -- Guardian Angel Group Inc. (GAGI.PK) is pleased to announce that the two companies are working diligently to complete the final merger agreement. John Gonzalez, the current President of Guardian Angel stated, "We hope to have the final agreement in place no later than February 26th 2010 ". Gonzales concluded, "While this is an aggressive schedule I believe it is one that is obtainable, I am excited for our company and its shareholders to be the new home of the biotechnology and advanced health sciences portfolio of Healthcare of Today, Inc."
Healthcare of Today has assembled an impressive list of holdings since its inception in 2008. The holding company uses a vertical integration model in the hopes of increasing efficiency for its constituent businesses, and furthermore passing savings to consumers. (www.healthcareoftoday.com)
Healthcare of Today CEO Henry Jan stated, "As the Healthcare of Today family of businesses has grown, we have modified our strategy or structure where needed to accommodate that growth and enable it further. We are proud of what we have accomplished so far, and are now optimistically examining what we can do for our shareholders in 2010."
The company plans for further details to be released on the forthcoming merger as they develop over the next 10 days.
Guardian Angel Group Identifys One Asset Of The New Biotech Division, Xenotis Pty Ltd. - Advanced Human Tissue Technology Producer
Houston, TX, Feb 17, 2010 (M2 PRESSWIRE via COMTEX) -- In December 2009 Healthcare of Today, Inc.announced the acquisition of Xenotis Pty Ltd. to its biotech division, the Australian-based producer of advanced human tissue engineering technology for $40M and now has been identified as one of the assets that will be included in the new bio-tech division of Guardian Angel Group (Pinsheets: GAGI).
"Xenotis is leading the world in advanced human tissue engineering. While many companies are interested in this fast-growing market, few have made the clear strides that Xenotis has. The company has working products and a strong distribution network in place around the globe. As we consider how to seamlessly integrate Xenotis into our biotech division, I think there is a particular dynamic to be enjoyed given our relationship with Regenetech, which is the world leader in advanced stem cell research technology," said Healthcare of Today CEO Henry Jan.
The recent growth of the tissue engineering industry has been attributed to the shortage of donors and the desire to avoid rejection. Xenotis has been involved in proprietary tissue scaffolds and processing techcnology since the late 1980's. Other medical devices and products in the company's tissue engineering portfolio include a range of tissue-engineered grafts, replacement blood vessels, ligaments and heart valves.<
Xenotis is well known for its custom-designed biosynthetic graft, produced according to strict specifications for use in peripheral bypass or arteriovenous access. The custom-designed prosthetic material combines the durability of synthetic material with similar hemocompatibility to that of a natural blood vessel. This stands in contrast to pure biological grafts, which are made from recycled blood vessels or other recovered tissues.
The prostheses is used when grafting from the patient's own blood vessel is not possible. Among its benefits are that it is non-toxic, non-calcifying, and has medium to long-term functionality, making it a more cost-effective solution. It may also allow the patient to undergo fewer procedures, a distinct advantage for seniors for whom general health considerations increase the risk of repeated surgical procedures. To date, the prostheses has been implanted in tens of thousands of patients across 30 countries, and is produced and sold through one of Xenotis's wholly-owned subsidiaries.
Healthcare of Today CEO Henry Jan also said, "Xenotis's work has changed the lives of patients throughout the world. Improving the quality and viability of people's lives is something we are quite passionate about here at Healthcare of Today and Guardian Angel Group. Considering that the United States is 50% of the world medical device market, we wholeheartedly support their entry into this market and into the lives of our core customers. We intend on using the relationships that Xenotis has built around the world to expand the reach of the other companies in the Healthcare of Today family so that all can improve the value to the shareholder."
Guardian Angel Group's President Speaks On His Thoughts Concerning The Pending Merger
Houston, TX, Feb 18, 2010 (M2 PRESSWIRE via COMTEX) -- Guardian Angel Group Inc's (Pinsheets: GAGI) president John Gonzalez would like to express his appreciation for the ongoing patients and understanding of all involved with the merger as well as the shareholders of Guardian Angel Group Inc. Mr. Gonzalez stated today, " I am excited what this merger between our two companies represents to our shareholders current and in the future." Gonzalez concluded, "I never would have imagined that I would see a merger of this magnitude come together in my tenure while fitting so well to our overall business structure and management philosophies, we as the board of directors are doing our level best and will continue to keep everyone involved apprised of the details as they develop."
The company still believes that they are on schedule and urge all shareholders to visit the two company's websites for up to date information.